title: Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors.
abstract: The extracellular matrix (ECM) is the complex network of proteins that surrounds cells in multicellular organisms. Due to its diverse nature and composition, the ECM has a multifaceted role in both normal tissue homeostasis and pathophysiology. It provides structural support, segregates tissues from one another, and regulates intercellular communication. Furthermore, the ECM sequesters a wide range of growth factors and cytokines that may be released upon specific and well-coordinated cues. Regulation of the ECM is performed by the extracellular proteases, which are tasked with cleaving and remodeling this intricate and diverse protein matrix. Accordingly, extracellular proteases are differentially expressed in various tissue types and in many diseases such as cancer. In fact, metastatic dissemination of tumor cells requires degradation of extracellular matrices by several families of proteases, including metalloproteinases and serine proteases, among others. Extracellular proteases are emerging as strong candidate cancer biomarkers for aiding and predicting patient outcome. Not surprisingly, inhibition of these protumorigenic enzymes in animal models of metastasis has shown impressive therapeutic effects. As such, many of these proteolytic inhibitors are currently in various phases of clinical investigation. In addition to direct approaches, aberrant expression of extracellular proteases in disease states may also facilitate the selective delivery of other therapeutic or imaging agents. Herein, we outline extracellular proteases that are either bona fide or probable prognostic markers in breast cancer. Furthermore, using existing patient data and multiple robust statistical analyses, we highlight several extracellular proteases and associated inhibitors (eg, uPA, ADAMs, MMPs, TIMPs, RECK) that hold the greatest potential as clinical biomarkers. With the recent advances in high-throughput technology and targeted therapies, the incorporation of extracellular protease status in breast cancer patient management may have a profound effect on improving outcomes in this deadly disease.
authors.affiliation: Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Roy
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Logan A
authors.initials: LA
authors.lastname: Walsh
keywords: ADAMs; ECM; MMPs; RECK; TIMPs; uPA
references.citation: Ann Oncol. 2013 Feb;24(2):362-369
references.pmid: 22967992
references.citation: Am J Pathol. 2006 Mar;168(3):715-7
references.pmid: 16507886
references.citation: Clin Chim Acta. 2000 Feb 15;291(2):113-35
references.pmid: 10675719
references.citation: Expert Rev Mol Diagn. 2014 Apr;14(3):347-63
references.pmid: 24649821
references.citation: Mol Cancer. 2013 Mar 25;12:22
references.pmid: 23522389
references.citation: Ann Oncol. 2008 Sep;19(9):1566-72
references.pmid: 18503039
references.citation: Adv Wound Care (New Rochelle). 2013 Feb;2(1):18-23
references.pmid: 24527319
references.citation: Development. 2012 Oct;139(20):3693-709
references.pmid: 22991436
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2335-43
references.pmid: 17438092
references.citation: Breast Cancer Res. 2006;8(5):R57
references.pmid: 17032447
references.citation: Biomarkers. 2012 Aug;17(5):416-21
references.pmid: 22515421
references.citation: Cell Tissue Res. 2010 Jan;339(1):83-92
references.pmid: 19921267
references.citation: Ann Oncol. 2002 Aug;13(8):1220-4
references.pmid: 12181245
references.citation: J Pathol. 2004 Apr;202(4):395-402
references.pmid: 15095266
references.citation: J Pathol. 2003 Jul;200(4):423-8
references.pmid: 12845610
references.citation: Cancer Cell. 2006 Jul;10(1):39-50
references.pmid: 16843264
references.citation: EMBO Mol Med. 2014 Feb;6(2):278-94
references.pmid: 24375628
references.citation: Virchows Arch. 2011 Sep;459(3):291-7
references.pmid: 21773755
references.citation: J Cell Mol Med. 2008 Dec;12(6B):2781-9
references.pmid: 18194466
references.citation: Asian Pac J Cancer Prev. 2014;15(3):1085-91
references.pmid: 24606423
references.citation: Cell. 2001 Dec 14;107(6):789-800
references.pmid: 11747814
references.citation: Cancer Sci. 2007 May;98(5):621-8
references.pmid: 17355265
references.citation: J Surg Oncol. 2010 Mar 1;101(3):259-69
references.pmid: 20039272
references.citation: Invest New Drugs. 2007 Aug;25(4):359-67
references.pmid: 17237909
references.citation: Genome Biol. 2011 Nov 11;12(11):233
references.pmid: 22078297
references.citation: Amino Acids. 2011 Jul;41(2):271-90
references.pmid: 20640864
references.citation: Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48
references.pmid: 20592239
references.citation: Pathophysiol Haemost Thromb. 2008;36(3-4):184-94
references.pmid: 19176991
references.citation: J Clin Invest. 2007 Feb;117(2):337-45
references.pmid: 17218988
references.citation: J Natl Cancer Inst. 2010 Jun 16;102(12):859-65
references.pmid: 20505152
references.citation: Dig Dis Sci. 2005 Nov;50(11):2081-9
references.pmid: 16240219
references.citation: Endocr Relat Cancer. 2010 Sep 23;17(4):R245-62
references.pmid: 20647302
references.citation: J Natl Cancer Inst. 2013 Jan 16;105(2):149
references.pmid: 23243205
references.citation: Cancer Res. 2004 Jul 1;64(13):4563-8
references.pmid: 15231667
references.citation: Clin Cancer Res. 2004 Apr 1;10(7):2289-98
references.pmid: 15073104
references.citation: Cell Tissue Res. 2010 Jan;339(1):237-46
references.pmid: 19513755
references.citation: Oncogene. 2014 Jul 31;33(31):4050-9
references.pmid: 24141782
references.citation: Science. 2002 Mar 29;295(5564):2387-92
references.pmid: 11923519
references.citation: Breast Cancer Res. 2007;9(1):R14
references.pmid: 17257442
references.citation: Blood. 2003 Aug 15;102(4):1186-95
references.pmid: 12714508
references.citation: Med Sci Monit. 2009 Feb;15(2):RA32-40
references.pmid: 19182722
references.citation: Br J Cancer. 2003 Oct 6;89(7):1270-5
references.pmid: 14520459
references.citation: Int J Oncol. 2009 Apr;34(4):897-903
references.pmid: 19287946
references.citation: Biomed Pharmacother. 2005 Oct;59 Suppl 2:S366-9
references.pmid: 16507411
references.citation: Neoplasma. 2014;61(4):439-46
references.pmid: 24645837
references.citation: Ann Oncol. 2008 Jun;19(6):1075-81
references.pmid: 18238782
references.citation: Gynecol Oncol. 2006 Aug;102(2):300-8
references.pmid: 16442153
references.citation: Cancer Sci. 2012 Jun;103(6):1084-9
references.pmid: 22404079
references.citation: Biochemistry (Mosc). 2013 Oct;78(10):1071-85
references.pmid: 24237141
references.citation: Clin Cancer Res. 1999 Mar;5(3):513-20
references.pmid: 10100701
references.citation: Dis Model Mech. 2011 Mar;4(2):165-78
references.pmid: 21324931
references.citation: J Drug Target. 2007 Jan;15(1):1-20
references.pmid: 17365270
references.citation: Med Clin (Barc). 2010 Feb 6;134(3):123-6
references.pmid: 19944435
references.citation: Med Res Rev. 2014 Sep;34(5):918-56
references.pmid: 24549574
references.citation: Biomed Pharmacother. 2013 Mar;67(2):179-82
references.pmid: 23201006
references.citation: Hematol Oncol Clin North Am. 2013 Aug;27(4):715-36, viii
references.pmid: 23915741
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2831-9
references.pmid: 15837997
references.citation: Histopathology. 2014 Mar;64(4):512-22
references.pmid: 24117661
references.citation: Curr Med Chem. 2011;18(4):513-22
references.pmid: 21143113
references.citation: Cancer. 2003 Jun 1;97(11):2710-5
references.pmid: 12767082
references.citation: Vitam Horm. 2013;93:307-21
references.pmid: 23810013
references.citation: Front Oncol. 2014 Feb 03;4:4
references.pmid: 24551591
references.citation: Cancer Res. 2008 Sep 1;68(17):7083-9
references.pmid: 18757423
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4245-53
references.pmid: 16963728
references.citation: Cancer Discov. 2012 May;2(5):401-4
references.pmid: 22588877
references.citation: Acta Neurol Belg. 2013 Dec;113(4):381-90
references.pmid: 24002649
references.citation: Postepy Hig Med Dosw (Online). 2008 Apr 07;62:141-7
references.pmid: 18414340
references.citation: Cancer Treat Rev. 2014 Apr;40(3):434-44
references.pmid: 24138841
references.citation: Curr Pharm Des. 2004;10(1):39-49
references.pmid: 14754404
references.citation: J Biol Chem. 2002 Mar 29;277(13):11201-7
references.pmid: 11790786
references.citation: Circ Res. 2003 May 2;92(8):827-39
references.pmid: 12730128
references.citation: Oncogene. 2015 Apr 23;34(17):2189-203
references.pmid: 24931164
references.citation: Int J Cancer. 2000 Mar 20;89(2):118-21
references.pmid: 10756061
references.citation: J Androl. 2009 May-Jun;30(3):259-74
references.pmid: 19136391
references.citation: Clin Chim Acta. 2010 Feb;411(3-4):234-41
references.pmid: 19914229
references.citation: J Biol Chem. 2002 Feb 8;277(6):4223-31
references.pmid: 11704682
references.citation: Curr Pharm Des. 2009;15(20):2359-74
references.pmid: 19601837
references.citation: Sci Signal. 2008 Jul 08;1(27):re6
references.pmid: 18612141
references.citation: J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
references.pmid: 11792750
references.citation: J Natl Cancer Inst. 2001 Jun 20;93(12):913-20
references.pmid: 11416112
references.citation: Cancer Prev Res (Phila). 2012 Feb;5(2):309-19
references.pmid: 22307566
references.citation: J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200
references.pmid: 21123617
references.citation: J Endocrinol. 2011 May;209(2):139-51
references.pmid: 21307119
references.citation: Oncogene. 1997 Jun 12;14(23):2767-74
references.pmid: 9190892
references.citation: Clin Proteomics. 2011 Jun 09;8(1):9
references.pmid: 21906355
references.citation: Cancers (Basel). 2014 Mar 25;6(2):684-707
references.pmid: 24670368
references.citation: Nat Rev Mol Cell Biol. 2007 Mar;8(3):245-57
references.pmid: 17299501
references.citation: J Clin Lab Anal. 2012 Feb;26(2):93-103
references.pmid: 22467324
references.citation: Mol Biotechnol. 2002 Sep;22(1):33-49
references.pmid: 12353913
references.citation: Clin Cancer Res. 2001 Jul;7(7):1912-22
references.pmid: 11448904
references.citation: Int J Cancer. 2008 May 1;122(9):2050-6
references.pmid: 18172859
references.citation: Front Biosci. 2006 Jan 01;11:544-69
references.pmid: 16146752
references.citation: Sci Signal. 2013 Apr 02;6(269):pl1
references.pmid: 23550210
references.citation: BMC Urol. 2012 May 29;12:14
references.pmid: 22642976
references.citation: Asian Pac J Cancer Prev. 2013;14(3):1615-21
references.pmid: 23679245
references.citation: Br J Cancer. 2013 Mar 5;108(4):766-70
references.pmid: 23412098
references.citation: J Signal Transduct. 2010;2010:985132
references.pmid: 21152266
references.citation: Nat Rev Cancer. 2002 Sep;2(9):657-72
references.pmid: 12209155
references.citation: Cancer Res. 2004 Dec 15;64(24):9062-9
references.pmid: 15604273
references.citation: J Natl Cancer Inst Monogr. 2010;2010(41):210-3
references.pmid: 20956832
references.citation: Immunol Lett. 2008 Jun 30;118(2):116-24
references.pmid: 18495253
references.citation: Cell. 2003 Jul 25;114(2):171-80
references.pmid: 12887919
references.citation: Am J Pathol. 2009 Sep;175(3):940-6
references.pmid: 19700750
references.citation: Biomed Res Int. 2013;2013:279505
references.pmid: 23762835
references.citation: J Cell Biol. 2012 Feb 20;196(4):395-406
references.pmid: 22351925
references.citation: J Clin Oncol. 2005 Feb 1;23(4):842-9
references.pmid: 15681529
references.citation: Crit Rev Biochem Mol Biol. 2010 Apr;45(2):146-69
references.pmid: 20184396
references.citation: Placenta. 2014 Feb;35 Suppl:S57-63
references.pmid: 24231445
references.citation: Anticancer Res. 2008 Mar-Apr;28(2B):1389-97
references.pmid: 18505085
references.citation: Pharmgenomics Pers Med. 2013 Dec 16;7:1-19
references.pmid: 24403841
references.citation: Nature. 2012 Apr 18;486(7403):346-52
references.pmid: 22522925
references.citation: Cancer Res. 2011 Apr 15;71(8):2988-99
references.pmid: 21363912
references.citation: Matrix Biol. 2014 Jan;33:35-40
references.pmid: 23896220